Biomaterials firm SINTX misses Q3 revenue estimates

Reuters

Nov 13

Biomaterials firm SINTX misses Q3 revenue estimates

Overview

SINTX Q3 revenue of $0.2 mln missed analyst expectations
Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln
Company strengthened liquidity with $4.3 mln raised through warrant exercises

Outlook

SINTX plans to launch the SINAPTIC wedge system in the near term
Company aims to expand clinical engagement in targeted surgical specialties
SINTX intends to leverage material science for polymer composites in implants

Result Drivers

FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product
FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs
STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$200,000	$400,000 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SINTX Technologies Inc is $25.00, about 86.3% above its November 12 closing price of $3.43

Press Release: ID:nGNX3fwCk3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583598524"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583598524\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583598524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583598524","market":"fut","top_or_hot":-1,"title":"Biomaterials firm SINTX misses Q3 revenue estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biomaterials firm SINTX misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>SINTX Q3 revenue of $0.2 mln missed analyst expectations</p></li><li><p>Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln</p></li><li><p>Company strengthened liquidity with $4.3 mln raised through warrant exercises</p></li></ul><p><span>Outlook</span></p><ul><li><p>SINTX plans to launch the SINAPTIC wedge system in the near term</p></li><li><p>Company aims to expand clinical engagement in targeted surgical specialties</p></li><li><p>SINTX intends to leverage material science for polymer composites in implants</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product</p></li><li><p>FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs</p></li><li><p>STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$200,000</p></td><td><p>$400,000 (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SINT\">SINTX Technologies Inc</a> is $25.00, about 86.3% above its November 12 closing price of $3.43</p></li></ul><p>Press Release: <span>ID:nGNX3fwCk3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomaterials firm SINTX misses Q3 revenue estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomaterials firm SINTX misses Q3 revenue estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biomaterials firm SINTX misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>SINTX Q3 revenue of $0.2 mln missed analyst expectations</p></li><li><p>Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln</p></li><li><p>Company strengthened liquidity with $4.3 mln raised through warrant exercises</p></li></ul><p><span>Outlook</span></p><ul><li><p>SINTX plans to launch the SINAPTIC wedge system in the near term</p></li><li><p>Company aims to expand clinical engagement in targeted surgical specialties</p></li><li><p>SINTX intends to leverage material science for polymer composites in implants</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product</p></li><li><p>FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs</p></li><li><p>STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$200,000</p></td><td><p>$400,000 (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SINT\">SINTX Technologies Inc</a> is $25.00, about 86.3% above its November 12 closing price of $3.43</p></li></ul><p>Press Release: <span>ID:nGNX3fwCk3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0JD:1","article_id":"2583598524","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583598524","pubTimestamp":1763039344,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biomaterials firm SINTX misses Q3 revenue estimatesOverviewSINTX Q3 revenue of $0.2 mln missed analyst expectationsOperating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mlnCompany st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","SINT":"SINTX Technologies Inc"},"translate_title":"生物材料公司SINTX未达到第三季度收入预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SINT":0.9},"content_text":"Biomaterials firm SINTX misses Q3 revenue estimatesOverviewSINTX Q3 revenue of $0.2 mln missed analyst expectationsOperating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mlnCompany strengthened liquidity with $4.3 mln raised through warrant exercisesOutlookSINTX plans to launch the SINAPTIC wedge system in the near termCompany aims to expand clinical engagement in targeted surgical specialtiesSINTX intends to leverage material science for polymer composites in implantsResult DriversFIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic productFACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costsSTRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercisesKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$200,000$400,000 (1 Analyst)Analyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for SINTX Technologies Inc is $25.00, about 86.3% above its November 12 closing price of $3.43Press Release: ID:nGNX3fwCk3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}